20 April 2022Jurisdiction reportsNaomi Pearce and Katrina Crooks

Australia: Achieving early generic/biosimilar market entry

These developments provide a swift and cost-effective path to remove patent barriers to generic/biosimilar market entry in Australia, where the market formation date is determined by an extended patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Australia reverses DABUS AI inventorship ruling

13 April 2022 The Federal Court of Australia has overturned its prior ruling that artificial intelligence (AI) can be a named inventor on a patent application, striking down the last year’s surprising win for Stephen Thaler and his ongoing AI inventorship campaign.

Patents

DABUS: decoding Australia’s AI decision

10 August 2021 Allowing an AI as an inventor could benefit the country’s pharma and drug discovery industries, say Richard Hamer, Lauren John and Alexandra Moloney of Allens.

Huawei wins seven-country ban on Netgear routers at the UPC

Lenovo faces US import ban as ITC sides with Ericsson

Arusha Protocol takes root: Fresh growth for plant variety protection in Africa

‘The politics of AI are developing’: Will Trump give tech a free ride?

China: Unpacking the first successful patent invalidation due to unauthorised foreign filing

SharkNinja overturns Dyson’s vacuum ban at the UPC

On our radar… Smashburger, OpenAI, Feminist Cyberlaw

IP strategy for AI should be a ‘living, breathing organism’

Australia: Achieving early generic/biosimilar market entry

More on this story

Editor's picks

Editor's picks

More articles